文献速递脊柱外科创伤骨科

术中万古霉素粉末对腰椎融合术后感染病原谱及药敏的影响

Effect of Intrawound Vancomycin Powder on the Pathogen Spectrum and Antimicrobial Susceptibility of Postoperative Infections in Elective Lumbar Fusion.
PubMed 文献 · Spine (Phila Pa 1976) · 2026-07-30

该研究为患者盲法单中心随机对照试验的二次微生物学分析,纳入292例择期后路腰椎椎间融合术患者,比较局部应用万古霉素粉末与对照组的术后手术部位感染病原谱、革兰染色分布、万古霉素及甲氧西林敏感性及非伤口感染率。结果显示万古霉素粉末未改变以革兰阳性菌为主的感染谱,未选择出万古霉素或甲氧西林耐药菌,对非伤口感染无全身影响。

要点

  • 局部万古霉素粉末未导致术后手术部位感染向革兰阴性菌偏移。
  • 未选择出万古霉素耐药、甲氧西林耐药或VRE、VRSA、MRSA菌株。
  • 两组非伤口感染发生率相当,以尿路病原体为主。

核心结论

  • 术中万古霉素粉末未改变以革兰阳性菌为主的手术部位感染病原谱,未选择出万古霉素或甲氧西林耐药菌,对非伤口感染无全身影响。

研究设计与样本

  • 患者盲法单中心随机对照试验的二次微生物学分析,2015年8月至2019年4月纳入择期后路腰椎椎间融合术成人,308例随机分组,292例分析(对照组n=152,万古霉素组n=140)。

主要发现

  • 革兰阳性菌在两组均占主导(对照组7/8[88%],万古霉素组3/3[100%]),无革兰阴性菌偏移。
  • 分离菌包括痤疮 Cutibacterium acnes(n=4)、MSSA、MRSE(各n=2)、S. saccharolyticus、E. cloacae及一例多微生物感染。
  • 万古霉素敏感性保留9/9(100%),未出现VRE、VRSA或MRSA,两株MRSE均来自对照组。
  • 非手术部位感染事件两组相当(8/152[5.3%] vs. 6/140[4.3%],P=0.788),以尿路病原体为主。

关键数值与推荐

  • 伤口培养按EUCAST折点判读,采用Fisher精确检验及Wilson 95%CI。
  • 万古霉素组在关闭切口前额外接受1 g万古霉素粉末,所有患者均接受静脉头孢呋辛。

临床怎么用

  • 腰椎融合术后怀疑手术部位感染时,经验性方案应保留革兰阳性菌覆盖。
  • 局部万古霉素粉末未显示选择耐药菌或增加非伤口感染的风险。

局限性

  • 为二次微生物学分析,感染事件数量少,可能影响耐药菌检出及组间比较的把握度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Secondary microbiological analysis of a patient-blinded, single-center randomized controlled trial. OBJECTIVE: To determine whether intrawound vancomycin powder alters the surgical site infection (SSI) pathogen spectrum and gram-status distribution, selects for vancomycin- or methicillin-resistant organisms, or affects the rate of non-wound infections after elective posterior lumbar interbody fusion. SUMMARY OF BACKGROUND DATA: Intrawound vancomycin powder is widely used to prevent SSI after lumbar fusion, but retrospective data raise concerns about a gram-negative pathogen shift and resistance selection; randomized evidence is limited. METHODS: Adults undergoing elective posterior lumbar interbody fusion were enrolled between August 2015 and April 2019. Of 308 randomized, 292 were analyzed (Control, n=152; Vancomycin, n=140). All received intravenous cefuroxime; Vancomycin patients additionally received 1 g vancomycin powder before closure. We assessed the SSI pathogen spectrum and gram-status distribution, vancomycin and methicillin susceptibility, and non-wound infection rates. Wound cultures were tested to EUCAST breakpoints; Fisher's exact test with Wilson 95% CIs was used. RESULTS: Gram-positive organisms dominated both groups (7 of 8 [88%] vs. 3 of 3 [100%]) with no gram-negative shift; isolates included Cutibacterium acnes (n=4), MSSA, MRSE (n=2 each), S. saccharolyticus, E. cloacae, plus one polymicrobial case. Vancomycin susceptibility was preserved in 9 of 9 (100%); no VRE, VRSA, or MRSA occurred; both MRSE isolates were Control. Non-SSI events were equivalent (8 of 152 [5.3%] vs. 6 of 140 [4.3%]; P=0.788), dominated by urinary-tract pathogens. CONCLUSIONS: Intrawound vancomycin powder did not alter the gram-positive-dominated SSI spectrum, did not select for vancomycin- or methicillin-resistant organisms, and had no systemic effect on non-wound infections. These randomized data support empiric regimens retaining gram-positive coverage when SSI is suspected after lumbar fusion. LEVEL OF EVIDENCE: Level of Evidence: 1b.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Panzenboeck LF, Duerrschnabel DL, Mitterer JA, et al. Effect of Intrawound Vancomycin Powder on the Pathogen Spectrum and Antimicrobial Susceptibility of Postoperative Infections in Elective Lumbar Fusion. Spine (Phila Pa 1976). 2026. PMID: 42531491. doi:10.1097/BRS.0000000000005809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。